Cancer
Researchers are investigating gamma delta T cell cancer therapy, a unique type of immunotherapy that uses a subset of T cells to recognize and destroy cancer cells. Unlike conventional immune therapies, gamma delta T cells can detect and target a wide variety of tumor types, including those not targeted by
Cancer
The CAR T cell therapy landscape has undergone significant transformations in the past decade, with multiple FDA-approved products now available for various B-cell malignancies. The current approvals include distinct products for large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, and acute lymphoblastic lymphoma. These therapies demonstrate remarkable
Cancer
Cancer researchers have made significant strides in understanding the role of tumor-infiltrating lymphocytes (TILs) in cancer immunotherapy. TILs are a diverse population of immune cells that play a crucial role in tumor immunity. A recent study published in Frontiers in Immunology has explored the phenotypic and functional diversity of TILs,
Cancer
Researchers at Fudan University have made a significant discovery in cancer immunotherapy, developing a new strategy that combines photodynamic therapy (PDT) with interleukin-15 (IL-15) to improve treatment outcomes. The study, published in the journal Pharmaceutics, used a co-hitchhiking delivery approach to enhance the therapeutic effect of PDT and IL-15, leading
Cancer
Researchers at Tianjin Medical University Cancer Institute and Hospital have made significant progress in understanding the mechanisms of T cell-based cancer immunotherapy, driven by advancements in T cell biology and innovative screening technologies. This comprehensive review examines T cell maturation, T cell-mediated antitumor responses, and the implications of thymic involution
Cancer
Researchers from Fujian Cancer Hospital have made a groundbreaking discovery in the field of nanotechnology, where they have successfully combined two small molecule inhibitors to enhance the anti-tumor immunity of CD8+ T cells. This novel strategy involves the co-encapsulation of SHP099, an allosteric inhibitor for Src-homology domain-containing protein tyrosine phosphatase-2
Cancer
Scientists at the National Cancer Institute (NCI) have discovered that the HTLV-1 p13 protein alters mitochondrial biology and T-cell function, leading to chronic life-long infection. This research, published in the journal Viruses, found that p13 affects mitochondrial respiration and promotes the recruitment of CD4+ T cells, the primary target of
Cancer
Researchers have made a groundbreaking discovery in the treatment of recurrent glioblastoma (rGBM), a deadly form of brain cancer. According to a preprint abstract on medrxiv.org, the rhino/poliovirus chimera, PVSRIPO, has shown objective radiographic responses with long-term survival in 20% of patients with rGBM. PVSRIPO works by infecting
Cancer
Research from Chung-Ang University, as stated in a recent study, highlights the multifaceted roles of tissue-resident memory T (TRM) cells in tumorigenesis and cancer immunotherapy. The study conducted by Eun Sang Seo, Sung-Kyu Lee, and Young Min Son, found that TRM cells, while offering protective functions in combating cancers, can
Cancer
Research conducted by the University of Oslo has yielded mixed results regarding the potential of thermal potentiation to enhance the effectiveness of cancer treatments. The study, which was published in the BMC Research Notes journal, aimed to investigate the relationship between body temperature and cancer resistance. The findings suggest that
Cancer
Investigations into the use of Janus kinase inhibitors (JAKi) in patients with cutaneous T-cell lymphoma (CTCL) have yielded promising results, according to a study published in The Journal of Dermatology. Researchers at Memorial Sloan-Kettering Cancer Center retrospectively analyzed the experience of their tertiary cancer center with JAKi in patients seen
